



Funding Opportunities in Horizon Europe

GLOHRA, 08.11.2023

Jan Skriwanek
National Contact Point Health
DLR-Project Management Agency



The National Contact Point Health Germany



National Contact Point Health at the DLR-Projektträger





Our Services

Information: Newsletter

Webpage - nksgesundheit.de

Information Events – in different regions

Consultancy On the phone, per E-Mail, personal meetings

Project idea – proposal – project implementation

EU Programming

Support Trainings – e.g. on proposal writing

Partner search (e.g. transnational brokerage events)









Horizon Europe





Health research in Horizon Europe





Horizon Europe Budget: ~ 95,5 Bio. €*



* Of which 5,4 Bio. € from Next Generation EU (for 2021-2024)



Global Challenges and Industrial Competitiveness

Objectives:

Gain of knowledge, development of technologies and solutions Contribution to solving global challenges

→ Topics referring to the Agenda 2030 for sustainable development (SDGs), the Paris Agreement on Climate and other policies (competitiveness, digitization, green deal,)



Characteristica of Pillar 2

- Top Down
- Mainly collaborative projects
 - min. 3 partners from 3 different Member States or Associated Countries
 - Partners from all over the world possible (not all receive funding)
 - Partners from academia, industry, public bodies, NGOs......
- Attractive funding rates (depending on the funding instrument) but mostly 100 % of eligible costs with flat rate of 25 % for indirect costs



Who is eligible for funding?

27 Member States (MS) of the EU

Associated Countries (AS)

EU Institutions (e.g. JRC) and International European research organisations

Third countries

High-income countriesOnly in exceptional cases*

Low and middle income countries

Funding











If participation is deemed essential

*

- If mentioned in the work programme
- Cluster Health: entities from the USA




Instruments used in Cluster Health 2023 / 2024

Research an Innovation Actions (RIA)	 Coordination and Support Actions (CSA)
 Collaborative Projects establish new knowledge, new or improved technologies, products, processes, services or solutions basic and applied research, technology development and integration, testing, demonstration and validation on a small-scale 	 Actions supporting the realisation of the programme (building networks, structuring a research field, organisation of events,)



Implementation of the Health Cluster






Work Programme Cluster Health 2023 / 2024

2024				
Procedure	Deadline			
Two-stage procedure	19.09.2023			
	11.04.2024			
One-stage procedure	11.04.2024			

- Threshold for funding: 12 pt. of 15 max. (differs from other parts of Horizon Europa)
- For all two-stage topics: Blind evaluation in 1st stage + lump sum funding



Structure of a work programme





Workprogramme 2023 / 2024 – Global Health

"[...] it is in the EU's strategic interest to also reach out and cooperate with other countries outside the EU and on other continents. This applies in particular for multi-lateral cooperation on (global) health issues with countries associated to Horizon Europe but also with other partner countries and regions in the world. In line with the EU's Global Approach to Research and Innovation, participation in Cluster 1 of Horizon Europe is open to third countries. In support of the Global Gateway Strategy, projects involving international partners should lead to increased scientific knowledge and transfer of technology among partner countries allowing to address global health challenges across the world, thus creating sustainable growth and jobs. Cooperation should take place in a value-based way, creating linkages, not dependencies [...]"



Destinations for Cluster Health

- 1. Staying healthy in a rapidly changing society
- 2. Living & working in a health-promoting environment
- 3. Tackling diseases & reducing disease burden
- 4. Ensuring access to innovative, sustainable & high-quality healthcare
- 5. Unlocking the full potential of new tools, technologies & digital solutions for a healthy society
- 6. Maintaining an innovative, sustainable & globally competitive health industry



Workprogramme 2023 / 24 – Open calls

Year	Research and Innovation Actions	Budget per Project / total
2024	HORIZON-HLTH-2024-TOOL-11-02-single-stage: Bio-printing of living cells for regenerative medicine	6-8 Mio. € / 25 Mio. €
2024	HORIZON-HLTH-2024-IND-06-08-single-stage: Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)	8-10 Mio. € / 10 Mio. €
2024	HORIZON-HLTH-2024-IND-06-09: Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators (CSA)	2. € / 2 Mio. €
2024	HORIZON-HLTH-2024-DISEASE-08-12: Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness (CSA)	2. € / 2 Mio. €
2024	HORIZON-HLTH-2024-DISEASE-08-20: Public health preparedness: Host-pathogen interactions of infectious diseases with epidemic potential	7-8 Mio. € / 50 Mio. €



Single-stage, deadline: 11.04.2024

Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential

<u>Topic description</u> of 2 pages, i.a.: Viral disease emergence is expected to accelerate due to among other factors, climate change, and thus a proactive approach to the development of vaccines and inhibitors for the cellular uptake of viruses in preparedness for future infectious disease outbreaks is needed. The availability of vaccines and candidates that inhibit cellular uptake of viruses would provide a critical preparedness measure against future health threats, in particular against pathogens with high pandemic potential meeting the criteria identified by the Health Emergency Preparedness and Response Authority (HERA). Proposals should focus on the following viruses: Hendra and Nipah virus, Lassa virus, Crimean Congo haemorrhagic fever virus, Rift Valley fever virus, Ebola and Marburg virus, Dengue virus, Yellow Fever virus, Zika virus, West Nile fever virus and Chikungunya virus. Proposals should address several of the following areas:

- Identification and characterisation of **receptors** on the host cell that enable the docking and internalisation of a virus with a particular emphasis on the diversity of cellular entry receptors and tissue specificity.
- Identification and characterisation of viral surface proteins that are capable of interacting with host target cells.

 Characterisation of the mechanism of viral uptake in the host cell with regard to the topology and the dynamics of the host receptor virus ligand interaction.

• Identification of receptor and ligand (sub)units that could be targeted by preventive or therapeutic intervention.




Horizon Europe Cluster Health - Outlook

- Work Programme 2025 Cluster Health actually under preparation, discussions with the Cluster Health program committe in 2024, publication foreseen for early 2025
- Work Programme 2026-2027



Funding & Tenders Portal



Search Funding & Tenders (europa.eu)

Work Programme Cluster Health 2023/24



Partner Search

- Funding & tender Portal (under each topic you can publish or look for expertise requests or offers)
- Funding & tender Portal partner search
- Cluster Health Brokerage Events
- IHI Call Days 4 & 5
- Ongoing projects (Cordis)
- HNN Guidelines for partner search



Cluster Health – useful links

- <u>EC Health research & innovation:</u> Overview & information on key research areas (Antimicrobial drug resistance (AMR), Brain research, Cancer, Cardiovascular diseases, Chronic diseases, Diabetes, Ebola, Emerging and reemerging infectious diseases, HIV/AIDS, Human development and ageing, Malaria, Public health research, Rare diseases, Tuberculosis, Zika
- <u>EU Global Health Strategy</u>
- Horizon Europe Cluster Health Info Day



Health NCPs exist in many countries

- All EU Member States
- All countries associated to Horizon Europe
- 25 third countries
- Find your NCP: <u>Funding & tenders (europa.eu)</u>
- Network of Health NCPs: <u>HNN3.0</u>



ACTIVITIES FOR:

NATIONAL CONTACT POINTs

APPLICANTS

TRAININGS & MENTORINGS

HEALTH RELATED BROKERAGE EVENTS enriched with Pitching sessions

STAFF EXCHANGE

TARGETED ACTIVITIES for widening countries

INFORMATION FLOW

WORKSHOPS

for targeting Widening countries

"EXCHANGE AND BUILD" WORKSHOPS with other networks and programmes

WORKSHOPS to inform applicants

NETWORKING & COLLABORATION with HE NCPs and Partnerships







PRODUCTS FOR:

NATIONAL CONTACT POINTS

NCPs TOOLKIT

WEBSITE

including a restricted area

HNN 3.0 SOCIAL MEDIA

HNN3.0 E-NEWLETTER for all actors

APPLICANTS

APPLICANT TOOLKIT

WEBSITE

calendar of calls and events

HNN 3.0 SOCIAL MEDIA

HNN3.0 E-NEWLETTER for all actors

SUCCESS STORIES








FOCUS on the Applicant Toolkit

Which products does it include?

- ANNOTATED TEMPLATES
- FACTSHEETS
- ONLINE TUTORIALS
- GUIDING DOCUMENTS
- O&A DOCUMENTS



Implementation of the Health Cluster





Innovative Health Initiative (IHI)



- Public-Private-Partnership
- Successor of the Innovative Medicines Initiative (IMI) with additional industries
- Initiative of the European Commission and Industry Associations from Pharma,
 Medtec, Digital Industries
- **Scope:** Precompetitive R&I to accelerate people-centered health interventions
- Financing:
 - o 1,2 Bio. € Cluster Health
 - + 1 Bio. € industries involved + 200 Mio. € contributing partner



IHI – Trade associations involved

Trade Association	Represents	Mission/Vision
efp <mark>t</mark> a	Pharmaceutical industry	To create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
COCIR	Medical imaging, radiotherapy, health ICT and electromedical industries	Our industry provides safe and high quality products and services, which contribute to reducing health inequalities and enhance cost efficiency in healthcare systems. COCIR's key objective is to promote free worldwide trade of innovative medical technology while maintaining the competitiveness of the European medical imaging, radiotherapy, electromedical and health ICT industries.
MedTech Europe from diagnosis to cure	Medical Technology industry	Make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.
Vaccines Europe An industry for frequity ives	Vaccine industry	To support broad access to immunisation, enabling better protection of the health of individuals and the wider community throughout life, with both existing vaccines and those in development.
EuropaBio	Biotech industry	Committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy.



Innovative Health Initiative (IHI)

- Topics are mainly initiated by industries
- Several calls per year
 - single-stage Calls
 - two-stage Calls
- Large scale transnational collaborative projects with large budgets
- Participation of companies mandatory
- Funding of large companies in principle possible
- Cofinancing of projects by the companies from the industry associations required (usually in kind)

innovative health initiative



IHI Calls

- Open Calls: Call 5 (single sage) Open calls | IHI Innovative Health Initiative (europa.eu)
- Forthcoming Calls (Opening ~ Q1 2024):

Future opportunities | IHI Innovative Health Initiative (europa.eu)

- IHI Call 6 (two stage)
- IHI Call 7 (single stage)
- Actually no topics in the area of Global Health
- Possiblity to propose future research ideas: Propose Ideas | IHI Innovative Health Initiative (europa.eu)



Get in touch with us!

Secretariat

+49 228 3821 - 1697

nks-gesundheit@dlr.de

www.nksgesundheit.de

Team

Kontakt - NKS Gesundheit